[Application of ultra-short gonadotropin-releasing hormone agonist protocol in controlled ovarian hyperstimulation].
OBJECTIVE
To study the effect of the ultra-short protocol of gonadotropin releasing hormone agonist (GnRH-a) combined with human menopausal gonadotropin (hMG) regimen for ovarian hyperstimulation.


METHODS
Setting clomiphene (CC)/human chronic gonadotropin (hCG) (50 cycles, 31 patients) and CC/hmg/hCG regimens (16 cycles, 16 patients who had failed in CC/hCG) as control groups, the ultra-short GnRH-a/hMG/hCG regimen (15 cycles, 15 patients who had failed in CC alone or CC/hMG regimens) as study group, the number of leading follicles, endometrial thickness, cervical mucus scores and hormone levels on the day of hCG administration, and the pregnancy rates were compared among of these three groups.


RESULTS
There was no premature luteotropic hormone (LH) surge in the ultra-short GnRH-a/hMG/hCG regimen group while there were three cycles in the CC/hMg/hCG group. The LH and progesterone (P) levels of ultra-short GnRH-a/hMG group on the day of hCG administration were lower than those of CC alone and CC/hMG groups. There were more leading follicles, greater endometrial thickness and cervical mucus score in the ultra-short GnRH-a/hMG group than those in CC alone and CC/hMG groups. The pregnancy rates per cycles in the three groups were similar.


CONCLUSIONS
The ultra-short GnRH-a/hMG regimen is a fairly good ovarian hyperstimulation regimen, especially for poor responders in CC alone or CC/hMG regimens.
Zhao
X
X
General Hospital, Jinan Command of PLA.
Zhang
L
L
Gong
S
S
D000328:Adult; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000627:therapeutic use*; D013480:Superovulation / Q000187:drug effects*
D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D007986:Luteinizing Hormone